Clinical application of montelukast treatment to pediatric asthma

Objective To discuss about the clinical effects of montelukast in treating pediatric asthma. Methods Eighty patients with pediatric asthma treated with montelukast in our hospital from July 2011 to August 2012 were analyzed by clinical data statistics to find the clinical results in 1, 4 weeks and 12 weeks treatment with its clinical effect scored and peak expiratory flow (PEF) and the change in first second forced expiratory volume (FEV 1 ) tested in order to determine the effect of montelukast in pediatric asthma treatment. Results Clinical statistics proved significantly improvement of health after the treatment of the 80 patients admitted. The initial score of PEF, FEV 1 , clinical effect were 108.25 ± 18.10, 72.45 ± 2.34, 5.66 ± 0.47, while in the end of the treatment cycle, the final score of PEF, FEV 1 , clinical effect were 140.21 ± 24.10, 92.10 ± 8.12, 3.21 ± 0.71, with statistically significant differences (P 0.05) existed. Conclusion Montelukast can effectively control the inflammation of the lungs of patients with pediatric asthma, relive suffering and improve health condition with sound treatment effects. It will help children sleep quality as well as improve the quality of life.